SynthesisFrontiers in immunology2026
Malignancies after vascularized composite allotransplantation.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Vascularized composite allotransplantation (VCA) has emerged as a reconstructive option for complex tissue defects, yet its oncologic long-term safety remains poorly characterized. Aims: This study aims to provide the most comprehensive overview of post-VCA malignancies to date. Methods and results: A systematic review was conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, searching PubMed/MEDLINE, EMBASE, and Web of Science for malignancies that emerged after VCA. Additionally, registry cases were identified through the Organ Procurement and Transplantation Network (OPTN). Risk of bias and methodological quality of included case reports were assessed using the Joanna Briggs Institute (JBI) Critical Appraisal Checklist for Case Reports and Case Series. The review protocol is registered on PROSPERO (CRD420261350024). 13 articles met the inclusion criteria, comprising 13 patients with 18 malignancies, reflecting multiple malignancies in individual patients. A total of 15 patients with 22 malignancies, including two additional OPTN registry cases, were analyzed. The most frequently diagnosed malignancies included non-melanoma skin cancer (NMSC; 41%; n=9/22 malignancies) and lymphoproliferative disorders (36%; n=8/22 malignancies). One malignancy was a recurrence in a patient who was transplanted due to squamous cell carcinoma of the mouth. Median time to malignancy was 24 (interquartile range [IQR]: 12-72) months after transplantation, malignancy-associated mortality was 33% (n=5/15 patients) and mean survival time after VCA was 74 ± 58 months in these patients. Notably, no malignancy was identified at the graft site and 23% (n=5/22) of malignancies led to a modification of the immunosuppressive regimen. Two patients self-reported symptoms prior to their scheduled follow-up, including cutaneous morphologic changes and systemic symptoms (night sweats, dyspnea, swelling). Conclusion: In our cohort, post-VCA malignancies were associated with a malignancy-associated mortality of 33%, with NMSC (41%) and lymphoproliferative disorders (36%) predominating the spectrum. Notably, two patients self-reported symptoms prior to their scheduled follow-up, suggesting that structured patient education may be warranted. Given the elective nature of VCA, careful patient selection, structured dermatologic screening, and Epstein-Barr virus surveillance may be useful to enable early detection of post-VCA malignancies. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD420261350024.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.